香港股市 已收市

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
26.03+0.15 (+0.58%)
收市:04:00PM EDT
26.72 +0.69 (+2.65%)
收市後: 07:51PM EDT

Genmab A/S

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

版塊Healthcare
行業Biotechnology
全職員工2,286

高階主管

名稱頭銜支付行使價出生年份
Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO2.87M1961
Mr. Anthony PaganoExecutive VP & CFO1.02M1978
Mr. Anthony ManciniExecutive VP & COO1.13M1971
Ms. Birgitte Stephensen M.Sc.Executive VP & Chief Legal Officer631.51k1961
Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer688.91k1971
Mr. Martin SchultzSenior Director of Clinical Operations & Non-Independent Director114.82k1976
Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer1.16M1958
Dr. Tahamtan AhmadiExecutive VP, Chief Medical Officer & Head of Experimental Medicines1.11M1973
Dr. Mijke Zachariasse Ph.D.Senior Director, Head of Antibody Research Materials & Non-Independent Director157.88k1974
Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director114.82k1975
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

公司管治

截至 2024年6月1日 止,Genmab A/S 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中:1;董事會:1;股東權利:1;現金賠償:9。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。